Skip to content
Open access

Intranasal human neural stem cell therapy in early-onset Parkinson's disease with motor complications: A randomized, double-blind, placebo-controlled trial.

Oct 2026 · Cell Transplantation · Vol 35, pp. 9636897261494929 · 0 citations · 50 references
Medicine

Abstract

BackgroundTo evaluate the safety and efficacy of intranasal transplantation of ANGE-S003 human neural stem cells (hNSCs) in early-onset Parkinson's disease (EOPD) patients with motor complications.MethodsIn this randomized, double-blind, placebo-controlled trial, 24 EOPD patients were randomized (2:1) to receive weekly intranasal administrations of 1.5 × 107 hNSCs or placebo for 4 weeks, followed by 12 months of follow-up. The primary endpoint was change in MDS-UPDRS Part IV score at month 6.ResultsNo significant difference was observed in the primary endpoint (least-squares mean difference, 0.42; 95% CI, -4.29 to 5.13; P = 0.853). Controls showed greater worsening of off-state MDS-UPDRS Part III motor scores in non-onset limbs at 12 months (P = 0.029). Exploratory 11C-CFT PET analyses demonstrated greater reductions in dopaminergic activity in the non-onset caudate (P = 0.022) and anterior putamen (P = 0.045) in controls versus the treatment group. A total of 137 adverse events and 6 serious adverse events were reported.ConclusionsAlthough the primary endpoint was not met, motor and neuroimaging findings provide preliminary signals of a potential treatment effect. Larger studies are needed to confirm efficacy and safety.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.